AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38727726 — intervention group
Group type: EXPERIMENTAL
Intervention: Evicel
Number of subjects: 40
Study 38727837 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus famitinib (20 mg once daily)
Number of subjects: 40
Study 38727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (PEG)
Number of subjects: 41
Study 38727860 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (ECU)
Number of subjects: 41
Study 38727860 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 41
Study 38727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab to Pegcetacoplan (ECU-to-PEG)
Number of subjects: 41
Study 38727945 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instrumentation and techniques for cup placement
Number of subjects: 170
Study 38728033 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure self-monitoring plus medication self-titration
Number of subjects: 312
Study 38728033 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study 38728244 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 23
Study 38728244 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 23
Study 38728323 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling/stepping in addition to conventional rehabilitation
Number of subjects: 0
Study 38728323 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 0
Study 38728337 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus best supportive care (BSC)
Number of subjects: 0
Study 38728337 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 0
Study 38728364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOXIRI (triplet arm)
Number of subjects: 146
Study 38728364 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus FOLFOX (doublet arm)
Number of subjects: 146
Study 38728564 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice hearing intervention
Number of subjects: 150
Study 38728564 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 150
Study 38728603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual diagnosis group (patients with substance use disorder and personality disorders)
Number of subjects: 118
Study 38728603 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients taking treatment for substance use disorder
Number of subjects: 118
Study 38728603 — intervention group
Group type: EXPERIMENTAL
Intervention: Females and alcohol abusers
Number of subjects: 118
Study 38728603 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SUD and PDs
Number of subjects: 118
Study 38728925 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP)
Number of subjects: 8
Study 38728925 — intervention group
Group type: COMPARATOR
Intervention: Heparin-mediated extracorporeal LDL-precipitation (HELP)-apheresis
Number of subjects: 8
Study 38729196 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 (0.5 mL intramuscular injections of modified vaccinia Ankara expressing H3N2 nucleoprotein and matrix protein 1)
Number of subjects: 145
Study 38729196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 38729196 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Number of subjects: 145
Study 38729343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular blood stasis imaging
Number of subjects: 66
Study 38729343 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography combining stasis and strain imaging
Number of subjects: 66
Study 38729390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans
Number of subjects: 45
Study 38729390 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Number of subjects: 45
Study 38729390 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAP reintroduction
Number of subjects: 45
Study 38729393 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fermentable oligo-, mono-, di-saccharides, and polyols (FODMAPs) diet (LFD)
Number of subjects: 0
Study 38729399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide 600 μg
Number of subjects: 74
Study 38729399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide 300 μg
Number of subjects: 74
Study 38729399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 38729426 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous atezolizumab (1875 mg)
Number of subjects: 371
Study 38729426 — intervention group
Group type: COMPARATOR
Intervention: Intravenous atezolizumab (1200 mg)
Number of subjects: 371
Study 38729426 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration
Number of subjects: 371
Study 38729426 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration
Number of subjects: 371
Study 38729550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapien 3/Sapien 3 Ultra Transcatheter Heart Valve (THV) series
Number of subjects: 1062
Study 38729550 — intervention group
Group type: COMPARATOR
Intervention: Myval/Myval Octacor THV series
Number of subjects: 1062
Study 38729567 — intervention group
Group type: EXPERIMENTAL
Intervention: Camizestrant monotherapy at doses of 25-450 mg once daily (QD)
Number of subjects: 108
Study 38729603 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Number of subjects: 176
Study 38729603 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 176
Study 38729603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TranS-C and PE
Number of subjects: 176
Study 38729628 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical findings (discomfort during active knee extension test)
Number of subjects: 330
Study 38729628 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to return to play (RTP)
Number of subjects: 330
Study 38729628 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight leg raise angle on the injured leg
Number of subjects: 330
Study 38729628 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of discomfort during active knee extension test
Number of subjects: 330
Study 38729628 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of oedema anteroposterior on MRI
Number of subjects: 330
Study 38729628 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotendinous junction (MTJ) involvement on MRI
Number of subjects: 330
Study 38729636 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg/day
Number of subjects: 290
Study 38729636 — intervention group
Group type: COMPARATOR
Intervention: Control (usual therapy without spironolactone)
Number of subjects: 290
Study 38729746 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 17
Study 38729747 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 10 mg/kg
Number of subjects: 34
Study 38729747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 38729747 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 34
Study 38729748 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (500 U/kg daily) for 9 days
Number of subjects: 50
Study 38729748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham injections)
Number of subjects: 50
Study 38729754 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment with reconstructive lymphatic surgery
Number of subjects: 180
Study 38729754 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment alone (control group)
Number of subjects: 180
Study 38729756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cerclage
Number of subjects: 238
Study 38729756 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no cerclage)
Number of subjects: 238
Study 38729773 — intervention group
Group type: EXPERIMENTAL
Intervention: NN414
Number of subjects: 13
Study 38729773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 38729814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-Care BR model
Number of subjects: 107372
Study 38729818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (569,600 IU)
Number of subjects: 61
Study 38729818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 38729951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin, flomoxef, and amikacin (combination regimens)
Number of subjects: 0
Study 38729951 — intervention group
Group type: COMPARATOR
Intervention: Current WHO recommended empiric regimens (ampicillin, gentamicin, cefotaxime)
Number of subjects: 0
Study 38730030 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered psychodynamic therapy (IPDT)
Number of subjects: 181
Study 38730030 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided internet-delivered psychodynamic therapy (IPDT)
Number of subjects: 181
Study 38730030 — intervention group
Group type: COMPARATOR
Intervention: Guided and unguided internet-delivered psychodynamic therapy (IPDT)
Number of subjects: 181
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute urosepsis with SOFA score ≥ 2 at diagnosis
Number of subjects: 354
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with respiratory failure at baseline
Number of subjects: 354
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission within the past 12 months
Number of subjects: 354
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstruction causative of urosepsis
Number of subjects: 354
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Urosepsis with multi-drug-resistant (MDR) pathogens
Number of subjects: 354
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA baseline score ≥ 2
Number of subjects: 354
Study 38730089 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 354
Study 38730096 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (monotherapy)
Number of subjects: 54
Study 38730096 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (first adjunctive therapy)
Number of subjects: 54
Study 38730247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanifibranor
Number of subjects: 0
Study 38730343 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological multiplex assays based on various antigen targets and antibody properties.
Number of subjects: 0
Study 38730363 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean Diet Adherence Screener (MEDAS) score (≥9 points)
Number of subjects: 4573
Study 38730363 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the Alternative Healthy Eating Index (AHEI-2010) (quartile 4)
Number of subjects: 4573
Study 38730363 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of fish and long-chain n-3 fatty acids (from MEDAS and AHEI-2010)
Number of subjects: 4573
Study 38730363 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of vegetables, nuts, and legumes (from AHEI-2010)
Number of subjects: 4573
Study 38730363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intake of trans-fat, sugar-sweetened beverages, and fruit juice (from AHEI-2010)
Number of subjects: 4573
Study 38730383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent electrical stimulation (IES) combined with routine care
Number of subjects: 548
Study 38730383 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 548
Study 38730382 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site Supportive Communication Training (On-site SCT) for three full days facilitated by a trained psychologist.
Number of subjects: 0
Study 38730382 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site Supportive Communication Training (On-site SCT)
Number of subjects: 0
Study 38730382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 38730398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based PrEP refills
Number of subjects: 106
Study 38730398 — intervention group
Group type: COMPARATOR
Intervention: Clinic-delivered PrEP services
Number of subjects: 106
Study 38730407 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking school bus intervention
Number of subjects: 418
Study 38730407 — intervention group
Group type: COMPARATOR
Intervention: Control (education materials)
Number of subjects: 418
Study 38730496 — intervention group
Group type: EXPERIMENTAL
Intervention: lecanemab 10 mg/kg biweekly
Number of subjects: 1795
Study 38730496 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1795
Study 38730496 — intervention group
Group type: EXPERIMENTAL
Intervention: lecanemab
Number of subjects: 1795
Study 38730548 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-directed radiotherapy with escalating functional liver radiation dose constraints (prescription dose 67.5-75 Gy in 15 fractions or 75-100 Gy in 25 fractions)
Number of subjects: 12
Study 38730548 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-directed radiotherapy
Number of subjects: 12
Study 38732635 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 116
Study 38732635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 38733160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (titrated to the maximum dose of 97/103 mg twice daily)
Number of subjects: 42
Study 38733160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 38733253 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1116
Study 38733253 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1116
Study 38733253 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class III/IV
Number of subjects: 1116
Study 38733340 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 150 mg/day and hydroxyurea 25 mg/kg/day for 3 months prior to alemtuzumab 1 mg/kg and 300 cGy TBI conditioning
Number of subjects: 20
Study 38733340 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine/hydroxyurea preconditioning
Number of subjects: 20
Study 38733387 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 174
Study 38733447 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker use
Number of subjects: 0
Study 38733447 — intervention group
Group type: COMPARATOR
Intervention: Target trial emulation of REDUCE-AMI
Number of subjects: 0
Study 38733554 — intervention group
Group type: EXPERIMENTAL
Intervention: NINJ1 expression levels in the TCGA cohort
Number of subjects: 135
Study 38733554 — intervention group
Group type: EXPERIMENTAL
Intervention: NINJ1 expression levels in the validation cohort
Number of subjects: 135
Study 38734015 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) and Islatravir (0·75 mg)
Number of subjects: 672
Study 38734015 — intervention group
Group type: COMPARATOR
Intervention: Baseline ART
Number of subjects: 672
Study 38734016 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (100 mg) and Islatravir (0·75 mg)
Number of subjects: 643
Study 38734016 — intervention group
Group type: COMPARATOR
Intervention: Bictegravir, Emtricitabine, and Tenofovir Alafenamide
Number of subjects: 643
Study 38734047 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating hot-cold water immersion (AHCWI)
Number of subjects: 24
Study 38734047 — intervention group
Group type: COMPARATOR
Intervention: Upper limb (UL) cycling exercises
Number of subjects: 24
Study 38734048 — intervention group
Group type: EXPERIMENTAL
Intervention: Decannulated patients
Number of subjects: 144
Study 38734048 — intervention group
Group type: EXPERIMENTAL
Intervention: Consciousness states at decannulation
Number of subjects: 144
Study 38734048 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in consciousness
Number of subjects: 144
Study 38734133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests and neuropsychological assessments
Number of subjects: 551
Study 38734133 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with comorbid ADHD (n=64)
Number of subjects: 551
Study 38734133 — intervention group
Group type: COMPARATOR
Intervention: General population of males with hemophilia
Number of subjects: 551
Study 38734138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment
Number of subjects: 200
Study 38734138 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment
Number of subjects: 200
Study 38734383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide 2 mg/day for 144 weeks
Number of subjects: 150
Study 38734383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide 10 mg/day for 144 weeks
Number of subjects: 150
Study 38734383 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment for 48 weeks followed by Bulevirtide 10 mg/day for 96 weeks
Number of subjects: 150
Study 38734439 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30
Study 38734439 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 38734654 — intervention group
Group type: EXPERIMENTAL
Intervention: MDSC immunosuppressive properties
Number of subjects: 61
Study 38734654 — intervention group
Group type: EXPERIMENTAL
Intervention: MDSCs from peripheral blood
Number of subjects: 61
Study 38734654 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immunosuppressive MDSCs
Number of subjects: 61
Study 38734654 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro functional assay
Number of subjects: 61
Study 38734659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention (Sophia Step Study)
Number of subjects: 83
Study 38734802 — intervention group
Group type: EXPERIMENTAL
Intervention: WISER intervention
Number of subjects: 506
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated before conception
Number of subjects: 83
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated during pregnancy
Number of subjects: 83
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated
Number of subjects: 83
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated before conception (infected group)
Number of subjects: 83
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated during pregnancy (infected group)
Number of subjects: 83
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated at 13-16 weeks gestation
Number of subjects: 83
Study 38734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated before conception (non-infected group)
Number of subjects: 83
Study 38735015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5464
Study 38735015 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 5464
Study 38735220 — intervention group
Group type: EXPERIMENTAL
Intervention: SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID
Number of subjects: 90
Study 38735220 — intervention group
Group type: EXPERIMENTAL
Intervention: SC trastuzumab
Number of subjects: 90
Study 38735220 — intervention group
Group type: COMPARATOR
Intervention: IV trastuzumab
Number of subjects: 90
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: S pyogenes pharyngeal carriage
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: S pyogenes skin carriage
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: S pyogenes pharyngitis
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: S pyogenes pyoderma
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: Household secondary attack rate for epidemiologically linked S pyogenes events
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: Household secondary attack rate for emm-linked S pyogenes events
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage acquisition clearance time
Number of subjects: 442
Study 38735305 — intervention group
Group type: EXPERIMENTAL
Intervention: emm-linked household transmission events
Number of subjects: 442
Study 38735354 — intervention group
Group type: EXPERIMENTAL
Intervention: nirmatrelvir/ritonavir
Number of subjects: 100
Study 38735354 — intervention group
Group type: COMPARATOR
Intervention: placebo/ritonavir
Number of subjects: 100
Study 38735424 — intervention group
Group type: EXPERIMENTAL
Intervention: White bystander acknowledgment and apology for racial exclusion
Number of subjects: 92
Study 38735424 — intervention group
Group type: COMPARATOR
Intervention: Racial exclusion (no acknowledgment)
Number of subjects: 92
Study 38735424 — intervention group
Group type: COMPARATOR
Intervention: Inclusion by White players in the ball-tossing game
Number of subjects: 92
Study 38735574 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine requirement for females aged 60-69 years
Number of subjects: 30
Study 38735574 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine requirement for females aged >70 years
Number of subjects: 30
Study 38735574 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine requirement for males (combined groups)
Number of subjects: 30
Study 38735912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity electrical stimulation (LIES)
Number of subjects: 40
Study 38735912 — intervention group
Group type: COMPARATOR
Intervention: Conventional en-masse retraction (CER)
Number of subjects: 40
Study 38736116 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg subcutaneously every 4 weeks
Number of subjects: 100
Study 38736216 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-Raman instrument
Number of subjects: 130
Study 38736216 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative diagnosis by Mohs surgeons
Number of subjects: 130